Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro

Combining bortezomib with other anti-cancer drugs or glucocorticoids is more efficient in multiple myeloma than bortezomib alone. However, the molecular mechanism of this beneficial effect is largely unknown. To investigate the effects of these compounds on bortezomib’s anti-proliferative potency an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schäfer, Julia (VerfasserIn) , Burhenne, Jürgen (VerfasserIn) , Weiß, Johanna (VerfasserIn) , Theile, Dirk (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2019
In: Naunyn-Schmiedeberg's archives of pharmacology
Year: 2018, Jahrgang: 392, Heft: 4, Pages: 461-466
ISSN:1432-1912
DOI:10.1007/s00210-018-01602-1
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00210-018-01602-1
Volltext
Verfasserangaben:Julia Schäfer, Jürgen Burhenne, Johanna Weiss, Dirk Theile

MARC

LEADER 00000caa a2200000 c 4500
001 1662546238
003 DE-627
005 20230426172422.0
007 cr uuu---uuuuu
008 190329r20192018xx |||||o 00| ||eng c
024 7 |a 10.1007/s00210-018-01602-1  |2 doi 
035 |a (DE-627)1662546238 
035 |a (DE-599)KXP1662546238 
035 |a (OCoLC)1341205800 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schäfer, Julia  |e VerfasserIn  |0 (DE-588)1147729913  |0 (DE-627)1006748164  |0 (DE-576)496019503  |4 aut 
245 1 0 |a Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro  |c Julia Schäfer, Jürgen Burhenne, Johanna Weiss, Dirk Theile 
264 1 |c 2019 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: 15 December 2018 
500 |a Gesehen am 29.03.2019 
520 |a Combining bortezomib with other anti-cancer drugs or glucocorticoids is more efficient in multiple myeloma than bortezomib alone. However, the molecular mechanism of this beneficial effect is largely unknown. To investigate the effects of these compounds on bortezomib’s anti-proliferative potency and its intracellular accumulation and potency to inhibit the chymotrypsin-like proteasomal subunit, seven myeloma cell lines were investigated after exposure to bortezomib alone or either combined with adriamycin plus dexamethasone (PAD regimen) or melphalan plus prednisolone (VMP regimen), respectively. PAD or VMP combinations did not alter cellular bortezomib uptake. However, PAD and VMP regimens increased bortezomib’s chymotrypsin-like subunit inhibitory potency. This likely originates from indirect proteasome modulation, because adriamycin, dexamethasone, melphalan, or prednisolone did not inhibit this subunit when used alone. Strikingly, the anti-proliferative potency of bortezomib was not enhanced but slightly lowered in some cell lines when used in combinations. Adriamycin, dexamethasone, melphalan, or prednisolone can enhance bortezomib’s chymotrypsin-like subunit inhibitory potency, likely by mechanisms indirectly influencing proteasome functionality. 
534 |c 2018 
650 4 |a Bortezomib 
650 4 |a Multiple myeloma 
650 4 |a PAD 
650 4 |a Proteasome inhibition 
650 4 |a VMP 
700 1 |a Burhenne, Jürgen  |d 1963-  |e VerfasserIn  |0 (DE-588)1034228889  |0 (DE-627)745126987  |0 (DE-576)381858197  |4 aut 
700 1 |a Weiß, Johanna  |e VerfasserIn  |0 (DE-588)1050230906  |0 (DE-627)783666322  |0 (DE-576)404441114  |4 aut 
700 1 |a Theile, Dirk  |e VerfasserIn  |0 (DE-588)1019114428  |0 (DE-627)684195658  |0 (DE-576)356996360  |4 aut 
773 0 8 |i Enthalten in  |t Naunyn-Schmiedeberg's archives of pharmacology  |d Berlin : Springer, 1873  |g 392(2019), 4, Seite 461-466  |h Online-Ressource  |w (DE-627)254638309  |w (DE-600)1462940-9  |w (DE-576)074531433  |x 1432-1912  |7 nnas  |a Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro 
773 1 8 |g volume:392  |g year:2019  |g number:4  |g pages:461-466  |g extent:6  |a Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro 
856 4 0 |u https://doi.org/10.1007/s00210-018-01602-1  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190329 
993 |a Article 
994 |a 2019 
998 |g 1019114428  |a Theile, Dirk  |m 1019114428:Theile, Dirk  |d 910000  |d 910100  |e 910000PT1019114428  |e 910100PT1019114428  |k 0/910000/  |k 1/910000/910100/  |p 4  |y j 
998 |g 1050230906  |a Weiß, Johanna  |m 1050230906:Weiß, Johanna  |d 910000  |d 910100  |e 910000PW1050230906  |e 910100PW1050230906  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1034228889  |a Burhenne, Jürgen  |m 1034228889:Burhenne, Jürgen  |d 910000  |d 910100  |e 910000PB1034228889  |e 910100PB1034228889  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1147729913  |a Schäfer, Julia  |m 1147729913:Schäfer, Julia  |d 910000  |d 910100  |e 910000PS1147729913  |e 910100PS1147729913  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1662546238  |e 3417398304 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"name":{"displayForm":["Julia Schäfer, Jürgen Burhenne, Johanna Weiss, Dirk Theile"]},"recId":"1662546238","person":[{"display":"Schäfer, Julia","given":"Julia","family":"Schäfer","role":"aut"},{"given":"Jürgen","display":"Burhenne, Jürgen","family":"Burhenne","role":"aut"},{"given":"Johanna","display":"Weiß, Johanna","family":"Weiß","role":"aut"},{"family":"Theile","role":"aut","display":"Theile, Dirk","given":"Dirk"}],"note":["Published online: 15 December 2018","Gesehen am 29.03.2019"],"title":[{"title":"Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro","title_sort":"Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"6 S."}],"id":{"doi":["10.1007/s00210-018-01602-1"],"eki":["1662546238"]},"relHost":[{"origin":[{"dateIssuedDisp":"1873-","publisher":"Springer","publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1873"}],"title":[{"title":"Naunyn-Schmiedeberg's archives of pharmacology","title_sort":"Naunyn-Schmiedeberg's archives of pharmacology"}],"id":{"zdb":["1462940-9"],"issn":["1432-1912"],"eki":["254638309"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"254638309","titleAlt":[{"title":"Archives of pharmacology"},{"title":"Archiv für experimentelle Pathologie und Pharmakologie"},{"title":"Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie"},{"title":"Naunyn-Schmiedebergs Archiv für Pharmakologie und experimentelle Pathologie"},{"title":"Naunyn-Schmiedebergs Archiv für Pharmakologie"}],"disp":"Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitroNaunyn-Schmiedeberg's archives of pharmacology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 19.10.05"],"pubHistory":["1.1873 -"],"language":["eng"],"part":{"text":"392(2019), 4, Seite 461-466","issue":"4","extent":"6","pages":"461-466","year":"2019","volume":"392"}}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}]} 
SRT |a SCHAEFERJUELUCIDATIN2019